id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353963-d3gk3519	Karampela, Irene	Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?	2020-06-06		.txt	text/plain	807	48	29	A recent in silico study has shown that the fluoroquinolones, ciprofloxacin and moxifloxacin, may inhibit SARS-CoV-2 replication by exhibiting stronger capacity for binding to its main protease than chloroquine and nelfinavir, a protease inhibitor antiretroviral drug. Based on their potential antiviral activity and immunomodulatory properties, the favorable pharmacokinetics and safety profile, we propose the use of respiratory fluoroquinolones as adjuncts in the treatment of SARS-CoV-2 associated pneumonia. However, preliminary clinical trials reported conflicting results regarding the use of the anti-malarial and anti-inflammatory chloroquine and the macrolide azithromycin, while the antiviral remdesivir has not been shown to significantly decrease COVID-19 mortality (1, 2) . Considering the potential antiviral activity of respiratory fluoroquinolones against SARS-CoV-2, along with their immunomodulatory properties, their favorable pharmacokinetics and the excellent safety profile, we propose their use as adjuncts in treating patients presenting COVID-19. Therefore, randomized clinical trials of respiratory fluoroquinolones are necessary to explore their potential Arch Med Res E20_832 3 therapeutic effect as an adjunct in the treatment of SARS-CoV-2 associated pneumonia.	./cache/cord-353963-d3gk3519.txt	./txt/cord-353963-d3gk3519.txt